Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group
- PMID: 9109743
- DOI: 10.1001/archneur.1997.00550160054016
Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group
Abstract
Objective: To determine if mortality is increased in individuals with human immunodeficiency virus type 1 (HIV-1)-associated neurocognitive disorders less severe than frank dementia.
Design: A prospective cohort study; median duration of follow-up was 2.4 years. Kaplan-Meier analysis and Cox proportional hazards models were used to compare survival times according to neurocognitive classification.
Setting: University-based research unit.
Participants: A volunteer sample of 414 individuals seropositive for HIV-1. Subjects were classified at their baseline evaluation as neuropsychologically (NP) normal or abnormal (impaired in > or = 2 NP test domains). A subgroup of NP abnormal subjects met operational criteria for HIV-associated minor cognitive motor disorder; the remaining subjects were designated NP impaired. Subjects with frank dementia were excluded.
Main outcome measure: Mortality.
Results: At the baseline evaluation, 256 (62%) of 414 subjects were designated normal; 109 (26%). NP impaired; and 49 (12%), minor cognitive motor disorder. One hundred six participants (26%) died during follow-up. Compared with the NP normal group, the unadjusted relative risk (RR) of death for all NP abnormal subjects (minor cognitive motor disorder and NP impaired) was significantly increased (RR, 1.7; 95% confidence interval [CI], 1.2-2.6; P < .005). After adjusting for concurrently measured predictors of survival (CD4 lymphocyte counts, Centers for Disease Control and Prevention HIV disease classification, hemoglobin concentration, and serum beta 2-microglobulin) in proportional hazards models, mortality for all NP abnormal subjects remained elevated (RR, 1.8; 95% CI, 1.2-2.8; P < .01). The elevation in mortality risk for subjects with minor cognitive motor disorder was statistically significant (RR, 2.2; 95% CI, 1.2-3.8; P < .01); for NP impaired subjects it was marginally significant (RR, 1.6; 95% CI, 1.0-2.8; P = .06).
Conclusions: The HIV-infected individuals with NP impairment had a higher risk of dying than those without impairment. This was particularly true for those meeting syndromic diagnostic criteria.
Similar articles
-
Predictors of mortality among HIV-infected women in Kigali, Rwanda.Ann Intern Med. 1992 Feb 15;116(4):320-8. doi: 10.7326/0003-4819-116-4-320. Ann Intern Med. 1992. PMID: 1733389
-
Neuropsychological impairment-associated visual field deficits in HIV infection. HNRC Group. HIV Neurobehavioral Research Center.Invest Ophthalmol Vis Sci. 1999 Feb;40(2):435-42. Invest Ophthalmol Vis Sci. 1999. PMID: 9950603
-
Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion.Arch Neurol. 2003 Oct;60(10):1406-12. doi: 10.1001/archneur.60.10.1406. Arch Neurol. 2003. PMID: 14568811 Clinical Trial.
-
[Neurocognitive disorders related to human immunodeficiency virus infection].Med Clin (Barc). 2009 May 30;132(20):787-91. doi: 10.1016/j.medcli.2008.12.025. Epub 2009 Apr 9. Med Clin (Barc). 2009. PMID: 19361818 Review. Spanish.
-
Evaluating the neurocognitive complications of SLE. Lessons from HIV disease.Ann N Y Acad Sci. 1997 Aug 14;823:18-43. doi: 10.1111/j.1749-6632.1997.tb48377.x. Ann N Y Acad Sci. 1997. PMID: 9292031 Review.
Cited by
-
Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action.Neuropsychol Rev. 2013 Mar;23(1):81-98. doi: 10.1007/s11065-013-9225-6. Epub 2013 Feb 16. Neuropsychol Rev. 2013. PMID: 23417497 Free PMC article. Review.
-
HIV-1 Tat Induces Unfolded Protein Response and Endoplasmic Reticulum Stress in Astrocytes and Causes Neurotoxicity through Glial Fibrillary Acidic Protein (GFAP) Activation and Aggregation.J Biol Chem. 2016 Oct 21;291(43):22819-22829. doi: 10.1074/jbc.M116.731828. Epub 2016 Sep 8. J Biol Chem. 2016. PMID: 27609520 Free PMC article.
-
Evidence-based treatment for HIV-associated dementia and cognitive impairment: why so little?PLoS Clin Trials. 2007 Mar 30;2(3):e15. doi: 10.1371/journal.pctr.0020015. PLoS Clin Trials. 2007. PMID: 17401455 Free PMC article. No abstract available.
-
Cognitive neuropsychology of HIV-associated neurocognitive disorders.Neuropsychol Rev. 2009 Jun;19(2):152-68. doi: 10.1007/s11065-009-9102-5. Epub 2009 May 22. Neuropsychol Rev. 2009. PMID: 19462243 Free PMC article. Review.
-
Improving Detection of HIV-Associated Cognitive Impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery.J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):332-338. doi: 10.1097/QAI.0000000000001224. J Acquir Immune Defic Syndr. 2017. PMID: 27828876 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous